Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Buy" from Analysts

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have earned a consensus rating of "Buy" from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $11.63.

A number of equities analysts recently issued reports on CMPX shares. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Leerink Partnrs upgraded shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday. D. Boral Capital reiterated a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Tuesday. Piper Sandler began coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price objective for the company. Finally, Guggenheim reaffirmed a "buy" rating and set a $12.00 target price on shares of Compass Therapeutics in a research report on Wednesday.

Compass Therapeutics Price Performance

Shares of CMPX traded down $0.09 during midday trading on Wednesday, hitting $1.61. The stock had a trading volume of 1,908,897 shares, compared to its average volume of 808,707. The stock's 50 day moving average is $2.81 and its 200 day moving average is $2.11. The firm has a market cap of $221.94 million, a PE ratio of -4.34 and a beta of 1.19. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08.

Remove Ads

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, equities research analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors have recently bought and sold shares of the business. MPM Bioimpact LLC boosted its position in Compass Therapeutics by 51.9% during the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock valued at $12,423,000 after acquiring an additional 2,926,002 shares in the last quarter. Enavate Sciences GP LLC bought a new stake in Compass Therapeutics during the fourth quarter valued at about $11,293,000. Tang Capital Management LLC grew its stake in Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock valued at $8,555,000 after purchasing an additional 4,087,005 shares during the last quarter. Rock Springs Capital Management LP grew its stake in Compass Therapeutics by 2.7% in the fourth quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company's stock valued at $8,380,000 after purchasing an additional 150,336 shares during the last quarter. Finally, Blue Owl Capital Holdings LP raised its holdings in Compass Therapeutics by 2.6% in the fourth quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company's stock worth $4,284,000 after purchasing an additional 75,000 shares in the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.